New formula aims to improve drug safety in pregnant transplant patients
NCT ID NCT07422012
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will develop a formula to more accurately measure active tacrolimus levels in pregnant women who have had a uterus transplant. Tacrolimus is an immunosuppressant drug that prevents organ rejection, but pregnancy changes how the body processes it. Researchers will analyze blood samples from 55 participants to create a model that adjusts for these changes, potentially leading to safer dosing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tacrolimus
- What this could lead to
- If successful, this could lead to safer and more effective tacrolimus dosing during pregnancy for uterus transplant recipients.
- What could go wrong
- This is an early modeling study, not a treatment trial. The formula may not improve outcomes or may be too complex for routine use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNBOUND TACROLIMUS IN PREGNANT UTERUS TRANSPLANT RECIPIENTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor University Center of Dallas
Dallas, Texas, 75246, United States